A Phase II Study of Anecortave Acetate for the Treatment of Exudative Age-Related Macular Degeneration
Status:
Completed
Trial end date:
2003-04-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine the concentration of anecortave acetate (15 or 30 mg
versus placebo) that is safe and effective for the inhibition of the growth of blood vessels
in the retina in patients with wet AMD.